Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Influenza vaccination.
- Who it may be relevant to
- Registry conditions: Myocardial Infarction, Decompensated Chronic Heart Failure, Acute Heart Failure (AHF), Pulmonary Embolism Acute. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Poland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge. In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.
Interventions
- Biological Influenza vaccination
Influenza vaccination pre-discharge in patients hospitalized for acute cardiac conditions
Primary outcome measures
- infection, unplanned cardiovascular hospitalization or cardiovascular death [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Acute cardiac hospitalization,
- Planned discharge home within the next 48 hours following completion of in-hospital treatment,
- No prior influenza vaccination for the current influenza season.
Exclusion criteria
- History of a severe adverse reaction to influenza vaccination,
- Allergy to any component of the vaccine to be administered,
- Discharge to another hospital for continuation of treatment or discharge to a long-term care facility,
- Antibiotic therapy to be continued after discharge.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Poland · 1 center
- Jan Mikulicz Radecki University Hospital in Wroclaw — Wroclaw
Identifiers
NCT: NCT07617376 · KB 355/2025, KB 171/2026 · IDUB.E261.24.014, NANO-9/RNZP · SUBD.A460.26.014